Kamada (KMDA) Free Cash Flow (2012 - 2026)
Kamada's (KMDA) quarterly Free Cash Flow came in at $20.2 million in Q2 2026, up 101.05% on a YoY basis from $10.0 million in Q2 2025, and up 2858.21% quarter-over-quarter from $682000.0 in Q1 2026.
Analysis
Kamada (KMDA) Free Cash Flow (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Free Cash Flow for 15 consecutive years, with $20.2 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Free Cash Flow rose 101.05% year-over-year to $20.2 million; the trailing twelve-month figure through Jun 2026 stood at $45.2 million (down 7.08% YoY), and the FY2025 full-year result was $35.3 million, down 39.42% from the prior year.
- Free Cash Flow climbed to $20.2 million in Q2 2026 per KMDA's latest filing, from $682000.0 in the prior quarter.
- Across five years, Free Cash Flow topped out at $24.3 million in Q3 2024 and bottomed at -$1.7 million in Q1 2023.
- Historically, Free Cash Flow has averaged $8.8 million across 5 years, with a median of $7.9 million in 2022.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow plunged 129.01% in 2023, then jumped 818.38% in 2024.
- Over 5 years, Free Cash Flow stood at $7.7 million in 2022, then rose by 4.73% to $8.1 million in 2023, then surged by 64.79% to $13.3 million in 2024, then retreated by 22.38% to $10.3 million in 2025, then jumped by 95.1% to $20.2 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered $20.2 million, $682000.0, and $10.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 3.49 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 3.43 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 1.01 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 572.80 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -563.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 408.00 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -268.64 Mn |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn | 20.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 20.18 Mn |
| Mar 31, 2026 | 682,000.00 |
| Dec 31, 2025 | 10.34 Mn |
| Sep 30, 2025 | 14.01 Mn |
| Jun 30, 2025 | 10.04 Mn |
| Mar 31, 2025 | 955,000.00 |
| Dec 31, 2024 | 13.32 Mn |
| Sep 30, 2024 | 24.34 Mn |
| Jun 30, 2024 | 16.97 Mn |
| Mar 31, 2024 | 3.70 Mn |
| Dec 31, 2023 | 8.08 Mn |
| Sep 30, 2023 | 2.65 Mn |
| Jun 30, 2023 | 2.85 Mn |
| Mar 31, 2023 | -1.73 Mn |
| Dec 31, 2022 | 7.72 Mn |
| Sep 30, 2022 | 7.11 Mn |
| Jun 30, 2022 | 11.57 Mn |
| Mar 31, 2022 | 5.98 Mn |
| Dec 31, 2021 | -4.23 Mn |
| Sep 30, 2021 | -1.15 Mn |